Anti-Candida sp. (CAND-0869) - 250 µg

2 - 8°C Wet Ice

Candida species are opportunistic fungal pathogens commonly associated with healthcare-associated infections (HAIs), particularly in immunocompromised and critically ill patients. Candida infections, also known as candidiasis or yeast infections, can manifest as a variety of clinical syndromes, including bloodstream infections, urinary tract infections, surgical site infections, and candidemia. The most frequently isolated species in the context of HAIs are Candida albicans, followed by non-albicans species like Candida glabrata, Candida parapsilosis, and Candida tropicalis. Risk factors for Candida HAIs include the use of broad-spectrum antibiotics, central venous catheterization, prolonged hospitalization, and immunosuppressive therapies. Candida species have the ability to form biofilms on medical devices, further complicating treatment and facilitating their persistence in healthcare environments. Due to the rising incidence of multidrug-resistant Candida strains, early diagnosis, appropriate antifungal therapy, and infection control measures are critical to effectively manage Candida-related HAIs and improve patient outcomes.

≥1.0 mg/ml